Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Lung Cancer Clinical Trials

A listing of Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (237) clinical trials

Inovio TRT-001: Telomerase DNA Immunotherapy in Breast Lung and Pancreatic Cancers

This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high risk breast, lung, or pancreatic cancer with no evidence of disease after surgery and adjuvant therapy. Subjects will be enrolled ...

Phase

Phase 1 Combination Study of MM-151 and MM-121

This is a two-part Phase 1, non-randomized, open-label study of MM-151 plus MM-121 in patients with advanced, heregulin-positive lung, head and neck, and colorectal cancers. In part 1 of the study cohorts of 3 or more patients will be treated at escalating doses of MM-151 in combination with MM-121 until ...

Phase

Study of Endostar Subcutaneous Injection in NSCLC

This is an open-label, single-arm study to assess the safety, tolerability and pharmacokinetics of Endostar subcutaneous injection in Chinese advanced NSCLC patients.

Phase

A Study of rSIFN-co in Subjects With Advanced Solid Tumors

The Dose-Escalation Cohort will consist of the Pretreatment Phase, the Treatment Phase, the Extension Phase, Discontinuation and Follow-up. The Pretreatment Phase will include a Consent and Screening Period. The Treatment Phase will consist of the Lead in Period and first 21-day cycle of treatment during which subjects will be monitored ...

Phase

Safety Tolerability and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

The primary objective is to assess the safety and tolerability of multiple doses of Simotinib Hydrochloride in NSCLC patients. The secondary objective is to determine the pharmacokinetic (PK) profile and explore the preliminary anti-tumor activity.

Phase

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

The NSCLC patients who experienced good clinical responses to an EGFR-TKI will inevitably develop acquired resistance. A great deal of research are focusing on this issue. Arsenic trioxide showed efficacy and safety in acute promyelocytic leukemia, multiple myeloma and other solid tumors. Moreover, preclinical studies showed arsenic trioxide can reduce ...

Phase

Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer

The phase 1 study evaluats RAD001 in combination with radiotherapy in non-small cell lung cancer. First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is ...

Phase

Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

OBJECTIVES: Primary - To describe the safety and toxicity of the combination of dasatinib and bevacizumab in patients with advanced solid tumors that have progressed on standard therapy. - To find the maximum tolerated dose or recommended phase II dose of this combination. - To describe the biochemical changes in ...

Phase

FR901228 and Flavopiridol in Treating Patients With Advanced Lung Esophageal or Pleural Cancer

OBJECTIVES: Primary - Determine the maximum tolerated dose and dose-limiting toxic effects of FR901228 (depsipeptide) when administered with flavopiridol in patients with advanced primary lung or esophageal cancer, malignant pleural mesothelioma, or lung or pleural metastases. - Determine the pharmacokinetics of this regimen in these patients. Secondary - Analyze gene ...

Phase

Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer

OBJECTIVES: - Primary - To assess the safety and tolerability of daily cilengitide by determining its dose-limiting toxicity and maximum-tolerated dose when combined with concomitant fractionated whole-brain radiation therapy in patients with brain metastases from lung cancer. - Secondary - To collect evidence of the best overall response rate, overall ...

Phase